Lutronic PicoPlus Exploratory Clinical Trial

Inclusion Criteria: * Male or Female * Adults between age 18 and 60 years old * Group A: Fitzpatrick skin type I - VI for unwanted tattoos and Group B: Fitzpatrick Skin Types I - IV for benign pigmented lesions and other conditions * Unwanted tattoo that contains single or multi-color ink, and * Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 2 to 4 weeks before the treatment * Ability to read, understand, and sign the Informed Consent Form * Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes. * Understands and accepts the obligation not to undergo any other procedures in the areas to be treated * Willing and able to comply with all study participation requirements including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study Exclusion Criteria: * If receiving treatment for unwanted tattoo: double tattoos (tattoo over tattoo), history of allergic reactions to pigments following tattooing, local anesthetics or topical antibiotics * If receiving treatment for benign pigmented lesions including melasma: history of use of a lightening medication (hydroquinone, tranexamic acid), isotretinoid (or retinoid), or light-sensitive medication in the last 6 months * Known cardiovascular disease or cardiac surgery that in the opinion of the investigator would interfere with study treatments * Previous interventions or treatment with another device in the target area within 6 months of enrollment or during the study * Pregnant or lactating or planning pregnancy before end of study * Presence of an active systemic, local skin disease, medication or condition that may affect wound healing or interfere with participation or treatment to the active area. * Active or recurrent cancer of current chemotherapy or radiation therapy * History of seizure disorders due to light * History of vitiligo, eczema, or psoriasis * History of connective tissue disease, such as systemic lupus erythematosus or scleroderma * History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation * History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen * History of keloid scarring, hypertrophic scarring or of abnormal wound healing. * History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications. * History of seizure disorders due to light. * Suffering from coagulation disorders or taking prescription anticoagulation medications * History of keloid scarring, hypertrophic scarring or of abnormal wound healing Any use of medication that is known to increase sensitivity to light according to Investigator's discretion * Excessive or recent significant tan in areas to be treated or unable/unlikely to refrain from tanning during the study * Current smoker or history of smoking within 3 months of study participation * Systemic use of corticosteroid or isotretinoin within 6 months of study participation * Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus * Any physical or mental condition including alcohol or drug abuse that in the opinion of the investigator could interfere with subject's suitability for inclusion in study